Related Experiment Video
Updated: Jul 18, 2026

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants
Published on: March 6, 2018
NTP-CERHR monograph on the potential human reproductive and developmental effects of methylphenidate
Insights
Methylphenidate (Ritalin) shows negligible concern for tics and minimal concern for growth restriction in children. However, data are insufficient to conclude on pregnancy loss or broader reproductive effects in humans.
Area of Science:
- Toxicology
- Reproductive Health
- Developmental Biology
Background:
- Methylphenidate is a widely prescribed central nervous system stimulant for ADHD and narcolepsy.
- Public concern exists regarding its effects on child development.
- The National Toxicology Program (NTP) Center for the Evaluation of Risks to Human Reproduction (CERHR) evaluated its reproductive and developmental toxicity.
Purpose of the Study:
- To assess the potential for methylphenidate to cause adverse effects on human reproduction and development.
- To address public concerns regarding methylphenidate's impact on child development.
Main Methods:
- Comprehensive review of available developmental studies in children and experimental animals.
- Evaluation of data by an Expert Panel.
- Consideration of public comments on the findings.
Main Results:
- Negligible concern for methylphenidate-induced tics and movement disorders at therapeutic doses.
- Minimal concern for methylphenidate-induced growth restriction, observed only at high doses in animal studies with reversible effects.
- Insufficient data to conclude on associations with pregnancy loss or general reproductive effects in humans.
Conclusions:
- Methylphenidate poses low risk for tics and growth issues in children.
- Further research is needed to determine reproductive risks in pregnant women and overall human reproductive safety.
- NTP-CERHR monographs provide comprehensive risk evaluations for federal agencies and the public.
Abstract:
The National Toxicology Program (NTP) Center for the Evaluation of Risks to Human Reproduction (CERHR) conducted an evaluation of the potential for methylphenidate to cause adverse effects on reproduction and development in humans. Methylphenidate was selected for evaluation because of 1) widespread usage in children, 2) availability of developmental studies in children and experimental animals, and 3) public concern about the effect of this stimulant on child development. Methylphenidate is a central nervous system stimulant approved by the U.S. Food and Drug Administration for the treatment of attention deficit hyperactivity disorder (ADHD) in persons 6 years of age and older and for narcolepsy. The results of this evaluation on methylphenidate are published in an NTP-CERHR monograph which includes: 1) the NTP Brief, 2) the Expert Panel Report on the Reproductive and Developmental Toxicity of Methylphenidate, and 3) public comments received on the Expert Panel Report. As stated in the NTP Brief, the NTP reached the following conclusions regarding the possible effects of exposure to methylphenidate on human development and reproduction. First, there is negligible concern for methylphenidate-induced tics and movement disorders. This conclusion is based on studies showing that children treated with therapeutic doses of methylphenidate have no evidence of movement disorders or tics due to the medication. Second, there is minimal concern for methylphenidate-induced growth restriction. This conclusion is based on growth restriction being observed in animal studies only at high doses of methylphenidate using a non-therapeutic route of exposure. The effect on growth was reversible. Finally, there are insufficient data to draw conclusions on 1) an association between methylphenidate therapy in pregnant women and pregnancy loss and 2) possible reproductive effects of methylphenidate in humans. NTP-CERHR monographs are transmitted to federal and state agencies, interested parties, and the public and are available in electronic PDF format on the CERHR web site http://cerhr.niehs.nih.gov/ and in printed text or CD-ROM from the CERHR.
More Related Videos
Related Concept Videos
Teratogenicity
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Mutagenicity and Carcinogenicity
Pharmacokinetics in Pediatric Patients: Drug Metabolism

